Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy for 2027?
Novo Nordisk's profit margins are running far above Bristol Myers, yet the cheaper valuation tells a different story about where the value sits.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.